上海神奇制药投资管理股份有限公司 关于股东股票质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 | 证券代码：A | 股 600613 | 股票简称：A | 股 神奇制药 | | 编号：2023-029 | | --- | --- | --- | --- | --- | --- | | B | 股 900904 | B | 股 神奇 B | 股 | | 2、本次质押股份不存在被用作重大资产重组业绩补偿等事项的担保或其他 保障用途的情形。 3、控股股东及其控股公司累计质押股份情况 重要内容提示： 上海神奇制药投资管理股份有限公司（以下简称"公司"或"本公 司"） 的股东贵州迈吉斯投资管理有限公司（以下简称"迈吉斯"）持有公司 88,001,946 股，占公司总股本 16.48%；本次质押 10,350,000 股，累计质押股份 51,750,000 股，占公司总股份数 9.69%，占其持有公司股份 58.81%。 公司控股股东贵州神奇控股（集团）有限公司（以下简称"神奇控股"） 神奇控股及其控股公司迈吉斯合计持有 ...

| 证券代码：A | 股 600613 | 股票简称：A | 股 神奇制药 | | 编号：2023-028 | | --- | --- | --- | --- | --- | --- | | B | 股 900904 | B | 股 神奇 B | 股 | | 上海神奇制药投资管理股份有限公司 关于股东部分股票解除质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 上海神奇制药投资管理股份有限公司（以下简称"公司"或"本公司"） 的股东贵州迈吉斯投资管理有限公司（以下简称"迈吉斯"）持有公司 88,001,946 股，占公司总股本 16.48%；办理了股票质押式回购交易，解除质押 18,600,000 股。本次解除质押后，迈吉斯累计质押股份 41,400,000 股，占公司 总股份数 7.75%，占其持有公司股份 47.04%。 公司控股股东贵州神奇控股（集团）有限公司（以下简称"神奇控股"） 及其控股的迈吉斯合计持有公司 208,663,566 股，占公司总股本 39.07%；累计 质押股份 80 ...

重要内容提示： ●会议召开时间： 2023 年 5 月 10 日（周三）15:00 至 17:00 ●会议召开方式：上证路演中心网络互动 ● 会议召开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com/） 为进一步加强与广大投资者的沟通交流，上海神奇制药投资管理股份有限公 司（以下简称"公司"）将参加"2023 年上海辖区上市公司年报集体业绩说明会" 活动，现将有关事项公告如下： 本次业绩说明会活动将采取网络的方式举行，投资者可以登录"上证路演中 心"网站（http://roadshow.sseinfo.com）或关注微信公众号上证路演中心参 与活动，活动时间为 2023 年 5 月 10 日（周三）15:00 至 17:00。投资者可于 2023 年 5 月 5 日（星期五）16:00 前通过公司邮箱 shanghaiys@126.com 进行提问。 公司将在说明会上对投资者普遍关注的问题进行回答。 届时公司的董事总经理冯斌先生、独立董事陈世贵先生、财务总监李发淼先 生和董事会秘书吴克兢先生将通过网络在线交流形式与投资者就 ...

Financial Performance - The company's operating revenue for Q3 2022 was ¥510,571,558.22, a decrease of 6.73% compared to the same period last year[7]. - Net profit attributable to shareholders was ¥23,472,714.69, an increase of 171.27% year-on-year[7]. - The net profit after deducting non-recurring gains and losses reached ¥26,566,007.86, up 229.29% from the previous year[7]. - Basic earnings per share were ¥0.04, representing a 119.75% increase year-on-year[7]. - Total operating revenue for the first three quarters of 2022 reached ¥1,712,817,975.79, a slight increase from ¥1,703,088,380.27 in the same period of 2021[20]. - Net profit for the first three quarters of 2022 was ¥56,932,916.95, up from ¥53,907,174.09 in the previous year, reflecting a growth of approximately 5.6%[21]. - The company's operating profit for the first three quarters of 2022 was ¥75,387,073.16, slightly down from ¥78,860,854.58 in 2021[21]. - The company reported a total comprehensive income of ¥43,819,934.28 for the first three quarters of 2022, down from ¥56,197,317.60 in the same period of 2021[22]. Cash Flow - Cash flow from operating activities was ¥159,891,524.42, reflecting a significant increase of 429.73% compared to the same period last year[7]. - The total cash inflow from operating activities for the first three quarters of 2022 was CNY 1,770,453,361.85, an increase from CNY 1,641,958,522.96 in the same period of 2021, representing a growth of approximately 7.85%[24]. - The net cash flow from operating activities was CNY 270,481,490.46, significantly higher than CNY 114,101,576.47 in the previous year, indicating a year-over-year increase of about 137.5%[24]. - The total cash outflow for operating activities was CNY 1,499,971,871.39, slightly down from CNY 1,527,856,946.49 in the previous year, indicating a decrease of about 1.8%[24]. - Cash inflow from financing activities totaled CNY 9,000,000.00, up from CNY 710,000.00 in the previous year, marking a substantial increase[25]. - The net cash flow from financing activities was CNY -113,198,364.85, compared to CNY -39,568,074.78 in the same period last year, indicating a worsening in financing cash flow[25]. Assets and Liabilities - Total assets at the end of the reporting period were ¥3,216,027,613.32, an increase of 2.13% from the end of the previous year[8]. - Total current assets as of September 30, 2022, reached ¥1,588,339,670.26, up from ¥1,445,855,256.17[16]. - Non-current assets totaled ¥1,627,687,943.06, down from ¥1,703,114,865.26 year-over-year[17]. - The total liabilities of the company as of the third quarter of 2022 amounted to ¥835,179,707.99, compared to ¥756,453,562.62 in the previous year, showing an increase of approximately 10.4%[22]. - The total equity attributable to shareholders was ¥2,333,166,388.39, a slight decrease from ¥2,344,283,894.81 in the previous year[22]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 44,737[14]. - The company has a total of 120,661,620 shares held by Guizhou Magic Investment Co., Ltd., representing 22.59% of total shares[14]. Research and Development - Research and development expenses increased by 30.39% during the reporting period[11]. - Research and development expenses increased to ¥36,536,409.04 in 2022 from ¥28,020,773.91 in 2021, representing a growth of about 30.5%[20]. Financial Expenses - The company reported a significant increase in financial expenses by 307.48% due to interest from project financing being included in financial costs[11]. - The company’s financial expenses increased to ¥9,200,529.27 in 2022 from ¥2,257,892.38 in 2021, indicating a significant rise in financial costs[20]. Accounts Receivable and Payables - Accounts receivable increased to ¥496,458,545.09 from ¥455,172,386.90 year-over-year[16]. - Other payables rose to ¥244,392,301.84 from ¥148,604,944.25 year-over-year[17]. - The company reported a significant increase in accounts receivable financing, which decreased to ¥105,686,194.12 from ¥147,701,457.06 year-over-year[16]. Cash and Cash Equivalents - Cash and cash equivalents as of September 30, 2022, amount to ¥630,833,391.19, an increase from ¥493,799,824.37 at the end of 2021[16]. - The ending balance of cash and cash equivalents was CNY 630,775,637.12, an increase from CNY 481,997,752.68 at the end of the same period last year, representing a growth of approximately 30.9%[25]. - The company received CNY 8,595,681.65 in tax refunds, compared to CNY 1,958,078.06 in the previous year, showing a significant increase[24].

Financial Performance - The company's operating revenue for 2021 was RMB 2,303,032,719, representing a 26.61% increase compared to RMB 1,819,006,691 in 2020[19]. - Net profit attributable to shareholders reached RMB 69,622,537, a significant increase of 120.41% from a loss of RMB 341,202,593 in 2020[21]. - The net profit after deducting non-recurring gains and losses was RMB 38,620,696, up 111.21% from a loss of RMB 344,510,890 in the previous year[22]. - Cash flow from operating activities increased by 85.94%, totaling RMB 184,263,469 compared to RMB 99,097,235 in 2020[19]. - Basic and diluted earnings per share were both RMB 0.13, a 120.31% increase from a loss of RMB 0.64 in 2020[20]. - The weighted average return on equity rose to 3.01%, an increase of 20.88 percentage points from -17.87% in 2020[20]. - The total assets at the end of 2021 were RMB 3,148,970,121, a 1.65% increase from RMB 3,097,971,351 at the end of 2020[19]. - The net assets attributable to shareholders increased by 2.94% to RMB 2,344,283,895 from RMB 2,277,367,601 in 2020[19]. - The company disposed of an investment subsidiary, generating an investment income of over RMB 28,100,000, contributing to the profit growth[22]. Dividend Distribution - The company plans to distribute a cash dividend of 1 RMB per 10 shares, totaling 53,407,162.8 RMB based on a total share capital of 534,071,628 shares as of December 31, 2021[4]. - The cash dividend policy is in compliance with the company's articles of association and has clear standards and ratios for distribution[200]. Risk Management - The company emphasizes that forward-looking statements regarding future plans and development strategies do not constitute a substantive commitment to investors, highlighting the importance of investment risk awareness[5]. - The company has detailed potential risks in the section discussing future development in the annual report[6]. - The company has not reported any non-operational fund occupation by controlling shareholders or related parties[6]. - There are no violations of decision-making procedures regarding external guarantees[6]. - The company is closely monitoring industry policy changes and regulatory risks, establishing a dynamic warning mechanism to adapt to new regulations and maintain profitability[155]. Research and Development - The company continues to innovate in drug research and development, achieving multiple technological advancements and applying for national patents[36]. - Research and development expenses rose to CNY 50.95 million, reflecting a 19.06% increase from the previous year[83]. - The company holds a total of 133 patents, including 84 invention patents, enhancing its market competitiveness[80]. - The company is increasing investment in R&D for traditional Chinese medicine products, focusing on optimizing production processes and enhancing quality control standards[112]. - The company is conducting evidence-based medical research on sodium cantharidate products to explore further indications and derivative development[113]. Market Position and Strategy - The company is focusing on brand building as a systematic project to enhance its industry position and brand image[44]. - The company has a market share leading position in its core product, the sodium cantharidate series, which is a unique product in the country[68]. - The company collaborates with well-known hospitals for clinical research and technology transfer, enhancing its competitive edge in the industry[73]. - The company is actively exploring the dermatology and chronic disease segments, emphasizing the development of unique and key products to address chronic diseases and skin conditions[146]. - The company is positioned to leverage policy advantages and market demand in the pharmaceutical sector, particularly in response to the COVID-19 pandemic and related healthcare needs[110]. Corporate Governance - The company has established a robust corporate governance structure to ensure independent operations and protect shareholder rights[169]. - The board of directors consists of 9 members, including 3 independent directors, meeting the requirement of one-third independence[170]. - The company has established performance evaluation standards and procedures for senior management[171]. - The company has implemented a management system for information disclosure to ensure timely and accurate information sharing with shareholders[171]. - The company respects the rights of stakeholders, including creditors and employees, to promote sustainable development[171]. Operational Efficiency - The company is committed to cost control and efficiency improvement through lean management initiatives, aiming to reduce production costs and enhance operational efficiency[150]. - The company is enhancing its internal control systems to mitigate operational risks and improve efficiency, focusing on compliance and risk prevention measures[151]. - The company has implemented online operations and remote video meetings to ensure stable product quality and market supply during the pandemic[157]. - The company is enhancing procurement management and establishing strategic inventory reserves to mitigate raw material cost pressures[159]. Employee Management - The total number of employees in the parent company and major subsidiaries is 1,371, with 7 in the parent company and 1,364 in subsidiaries[194]. - The workforce includes 514 production personnel, 115 sales personnel, 221 technical personnel, 47 financial personnel, and 474 administrative personnel[194]. - The company emphasizes performance-based salary structures, linking employee compensation to company and individual performance[195]. - Future adjustments to the salary system will consider operational results and local market conditions to enhance employee benefits[196]. - The company has implemented targeted training programs to improve employee skills and overall management levels[197].

2021 年第三季度报告 证券代码：600613 证券简称：神奇制药 900904 神奇 B 股 上海神奇制药投资管理股份有限公司 2021 年第三季度报告 2021 年 10 月 1 / 13 2021 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 报表信息的真实、准确、完整。 第三季度财务报表是否经审计 单位：元 币种：人民币 | 项目 | 本报告期 | 本报告期 比上年同 | 年初至报告期末 | 年初至报告期 末比上年同期 | | | --- | --- | --- | --- | --- | --- | | | | 期增减变 | | 增减变动幅度 | | | | | 动幅度(%) | | (%) | | | 营业收入 | 547,399,983.42 ...

Financial Performance - The company's operating revenue for the first half of 2021 reached ¥1,155,688,396.85, representing a 37.69% increase compared to ¥839,327,318.01 in the same period last year[20]. - The net profit attributable to shareholders of the listed company was ¥44,371,523.59, up 55.52% from ¥28,530,267.49 in the previous year[20]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥45,681,482.77, an increase of 48.85% compared to ¥30,688,798.42 in the same period last year[20]. - The net cash flow from operating activities was ¥83,918,218.30, showing a significant increase of 113.64% from ¥39,280,109.64 in the previous year[20]. - Basic earnings per share increased by 33.33% to CNY 0.08 compared to the same period last year[21]. - Net profit attributable to shareholders increased by 55.52%, amounting to CNY 1,584.13 million, primarily due to growth in pharmaceutical manufacturing sales[22]. - Operating cash flow increased by 113.64%, reaching CNY 4,463.81 million, driven by increased sales revenue[22]. - The total comprehensive income for the first half of 2021 was CNY 37,793,885.71, up from CNY 30,553,561.52 in the first half of 2020, representing a growth of 23.3%[117]. Assets and Liabilities - The total assets at the end of the reporting period were ¥3,114,003,027.90, a slight increase of 0.52% from ¥3,097,971,351.94 at the end of the previous year[20]. - The total liabilities decreased to ¥46,858,516.86 from ¥49,467,819.40, indicating a reduction of approximately 5.4%[114]. - The company's total assets as of June 30, 2021, were ¥2,013,511,931.94, a slight decrease from ¥2,026,364,001.01 at the end of 2020[114]. - The total liabilities at the end of the reporting period were CNY 1,046,961,549.50, which is an increase from CNY 1,018,431,282 in the previous year, representing a growth of approximately 2.8%[145]. - The company's long-term equity investment totaled CNY 2.6793 million, primarily in Sichuan Magic Kangzheng Pharmaceutical Co., Ltd.[56]. Revenue Sources - Revenue from pharmaceutical manufacturing increased by CNY 239.36 million, a growth of 47.08%, with cold and cough products seeing a significant increase of 277.14%[21]. - The proportion of revenue from pharmaceutical manufacturing accounted for 65.56% of total revenue during the reporting period[27]. - The pharmaceutical manufacturing industry achieved a revenue of CNY 1,404.69 billion in the first half of 2021, representing a year-on-year increase of 28%[32]. Research and Development - The company focuses on R&D in eight major therapeutic areas, including anti-tumor and cardiovascular drugs, to enhance its industry competitiveness[28]. - Research and development expenses rose by 21.05% to ¥17,246,284.34, reflecting the company's commitment to enhancing product competitiveness[52]. - The company emphasizes the development of patent technology to protect its core product intellectual property[42]. Market and Competitive Position - The company has established a comprehensive marketing system covering most regions of the country, enhancing its competitive advantage[27]. - The company has optimized its marketing layout and strengthened control over commercial channels to improve market coverage and product penetration[44]. - The company is positioned to benefit from the growing demand for traditional Chinese medicine, supported by favorable government policies[40]. Risks and Challenges - The company has detailed various risks faced in its production and operation processes in the report[8]. - The ongoing COVID-19 pandemic has caused a decline in product sales due to lockdowns and reduced hospital visits, with uncertainty regarding the duration and extent of the impact[67]. - Rising raw material prices and the inability to pass costs onto consumers pose a risk to the company's profit margins, necessitating strategic procurement and inventory management[73]. - The ongoing national medical reform and dynamic adjustment of drug prices may impact the company's bidding success and pricing strategies[71]. Corporate Governance and Compliance - The company has not proposed any profit distribution plan or capital reserve transfer to increase share capital for this reporting period[6]. - The company has not faced any major litigation or arbitration matters during the reporting period[88]. - The actual controller and major shareholders of the company have maintained a good integrity record without any administrative or criminal penalties related to the securities market[88]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 46,656[98]. - The largest shareholder, Guizhou Shenqi Investment Co., Ltd., holds 131,301,620 shares, representing 24.59% of the total shares[100]. - The second-largest shareholder, Guizhou Maijisi Investment Management Co., Ltd., holds 88,001,946 shares, accounting for 16.48% of the total shares[100]. Financial Reporting and Standards - The company's financial statements were approved by the board of directors on April 30, 2021, ensuring compliance with regulatory standards[156]. - The financial statements are prepared in accordance with the Chinese Accounting Standards, reflecting the company's financial position, operating results, and cash flows accurately[160]. - The company recognizes cash equivalents as short-term, highly liquid investments that are easily convertible to known amounts of cash[173].

Financial Performance - Total revenue for Q1 2021 reached RMB 552.79 million, a 61.17% increase compared to RMB 342.99 million in the same period last year[10] - Net profit attributable to shareholders was RMB 21.80 million, representing a 151.21% increase from RMB 8.68 million year-on-year[5] - Operating cash flow net amount was RMB 53.02 million, a significant increase of 255.71% compared to RMB 14.90 million in the previous year[10] - The weighted average return on net assets increased to 0.93%, up 181.82% from 0.33% in the previous year[5] Investment and Expenses - Research and development expenses surged by 391.16% to RMB 9.55 million, reflecting the company's increased investment in R&D[10] - The company’s sales expenses increased by 105.29% to RMB 247.87 million, driven by higher sales revenue[10] Assets and Liabilities - Total assets at the end of the reporting period were RMB 3.16 billion, up 2.14% from RMB 3.10 billion at the end of the previous year[5] - The company reported a significant increase in accounts receivable, which rose by 121.60% to RMB 53.94 million due to increased revenue and bank acceptance bill collections[9] Shareholder Information - The number of shareholders at the end of the reporting period was 42,952, indicating a stable shareholder base[6] - The company has no overdue commitments or significant changes in expected cumulative net profit for the year[10]

Financial Performance - The company's operating revenue for 2020 was approximately ¥1.82 billion, a decrease of 5.63% compared to ¥1.93 billion in 2019[22]. - The net profit attributable to shareholders for 2020 was a loss of approximately ¥341.20 million, a decline of 506.32% from a profit of ¥83.97 million in 2019[22]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was approximately -¥344.51 million, down 519.06% from ¥82.21 million in 2019[22]. - The net cash flow from operating activities for 2020 was approximately ¥99.10 million, a decrease of 22.75% from ¥128.28 million in 2019[22]. - The total assets at the end of 2020 were approximately ¥3.10 billion, a decrease of 12.88% from ¥3.56 billion at the end of 2019[22]. - The net assets attributable to shareholders at the end of 2020 were approximately ¥2.28 billion, down 12.98% from ¥2.62 billion at the end of 2019[22]. - The company's basic and diluted earnings per share for 2020 were both -0.64 yuan, a decrease of 500.00% compared to 0.16 yuan in 2019[23]. - The total profit for 2020 was -340.28 million yuan, representing a year-on-year decline of 414%[77]. - The net profit attributable to shareholders was -341.20 million yuan, down 506.32% year-on-year, with a diluted earnings per share of -0.64 yuan, a decrease of 500%[77]. Operational Challenges - The company will not distribute cash dividends or bonus shares for the year 2020 due to operational losses and significant investment needs for the Sha Wen project[6]. - The net profit attributable to shareholders decreased by 506.32% year-on-year, primarily due to a provision for bad debts of 175.07 million yuan and goodwill impairment of 162.07 million yuan[24]. - Operating revenue for the reporting period decreased by 5.63% year-on-year, mainly due to a decline in pharmaceutical sales caused by the COVID-19 pandemic[24]. - The net cash flow from operating activities decreased by 22.75% year-on-year, primarily due to a reduction in cash received from sales[24]. - The company reported a net profit of -175.49 million yuan in Q3 2020 and -194.24 million yuan in Q4 2020, indicating ongoing financial challenges[27]. Research and Development - Research and development expenses increased by 114.39% year-on-year, indicating a significant investment in innovation[24]. - The company has established a comprehensive R&D system focusing on eight major therapeutic areas, enhancing its competitive edge in the pharmaceutical industry[35]. - The company is advancing the Shawan production and R&D industrial park, with 11 production lines ready and awaiting GMP compliance checks[88]. - The company is actively engaged in the research and development of ethnic medicinal materials, enhancing quality standards and product reserves[86]. - The company has ongoing research projects for sodium cantharidate vitamin B6 injection, targeting liver cancer and other conditions, with plans for clinical application[134]. Market Dynamics - The pharmaceutical manufacturing revenue accounted for 65.56% of total operating revenue, while pharmaceutical commercial revenue accounted for 34.44%[34]. - The pharmaceutical manufacturing segment saw a revenue decrease of CNY 25,415,080, a decline of 17.57%[97]. - The pharmaceutical commercial segment, however, increased revenue by CNY 14,556,430, an increase of 30.27%[97]. - The overall revenue for the pharmaceutical commercial sector was ¥5,416.91 billion, reflecting a growth of 3.40%, with net profit increasing by 12.79% to ¥143.24 billion, supported by the performance of retail chain pharmacies[60]. - The COVID-19 pandemic significantly impacted the pharmaceutical industry, leading to a decline in revenue and profits in Q1 2020, but a recovery was observed by June with profit growth turning positive[42]. Regulatory and Compliance - The company has received a standard unqualified audit report from its accounting firm, indicating the financial statements are accurate and complete[5]. - The company has passed all regulatory inspections with no instances of non-compliance, ensuring high product quality and safety[73]. - The company adheres to a centralized procurement strategy, ensuring compliance and efficiency in sourcing raw materials and packaging, with a focus on quality and safety in production processes[36]. - The company is adapting to regulatory changes in the pharmaceutical industry, including the implementation of the MAH system to promote innovation and resource optimization[68]. - The national medical insurance catalog adjustments in 2020 included 162 drugs, with 119 successfully negotiated, affecting the competitiveness of the company's prescription products[168]. Environmental and Social Responsibility - The company emphasizes environmental protection and has increased investment in pollution control measures to align with national sustainable development goals[196]. - The Longli branch upgraded its wastewater treatment system in early 2018, which has been operating well since September 2018, ensuring compliance with environmental regulations[198]. - The company actively responded to the COVID-19 pandemic by organizing the production of necessary medicines and donated medical supplies to frontline workers in Wuhan and impoverished areas in Guizhou Province[195]. - The Longli branch's environmental monitoring data is shared on the national pollution source monitoring information management platform to ensure timely and accurate reporting[199]. - The company has been recognized for its contributions to pandemic prevention and poverty alleviation, receiving honors from the All-China Federation of Industry and Commerce[195]. Strategic Initiatives - The company plans to focus on expanding its pharmaceutical commerce segment to offset declines in manufacturing revenue[100]. - The company is exploring new product development and market expansion strategies to enhance future growth prospects[100]. - The company aims to enhance brand value and market influence through continuous innovation and quality improvement[152]. - The company will pursue both internal innovation and external acquisitions to expand its product offerings and scale[153]. - The company recognizes the growing potential of the health industry post-pandemic and plans to leverage e-commerce channels and community platforms to drive product growth[162].

2021 年第一季度报告 公司代码：600613 公司简称：神奇制药 900904 神奇 B 股 上海神奇制药投资管理股份有限公司 2021 年第一季度报告 2021 年 4 月 1 / 21 | 一、 | 重要提示 3 | | --- | --- | | 二、 | 公司基本情况 3 | | 三、 | 重要事项 5 | | 四、 | 附录 7 | 2021 年第一季度报告 一、 重要提示 二、 公司基本情况 2.1 主要财务数据 | | 本报告期末 | 上年度末 | 本报告期末比上年度 | | --- | --- | --- | --- | | | | | 末增减(%) | | 总资产 | 3,164,307,522.46 | 3,097,971,351.94 | 2.14 | | 归属于上市公司 | 2,293,246,742.62 | 2,277,367,601.10 | 0.70 | | 股东的净资产 | | | | | | 年初至报告期末 | 上年初至上年报告期末 | 比上年同期增减(%) | | 经营活动产生的 | 53,017,693.53 | 14,904,611.03 | 255.71 | | ...